Latest Insider Transactions at Recursion Pharmaceuticals, Inc. (RXRX)
This section provides a real-time view of insider transactions for Recursion Pharmaceuticals, Inc. (RXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RECURSION PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RECURSION PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 05
2025
|
Najat Khan Chief R&D Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84,925
+10.13%
|
-
|
|
Nov 04
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Nov 04
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-3.94%
|
$200,000
$5.21 P/Share
|
|
Nov 04
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
60,000
+5.59%
|
-
|
|
Oct 23
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$500,000
$5.7 P/Share
|
|
Oct 23
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Oct 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Oct 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.31%
|
$600,000
$6.04 P/Share
|
|
Oct 10
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
120,000
+10.05%
|
-
|
|
Oct 01
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,941
+2.08%
|
-
|
|
Oct 01
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,961
+0.16%
|
-
|
|
Sep 25
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$400,000
$4.76 P/Share
|
|
Sep 25
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Sep 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,057
-0.87%
|
$28,228
$4.83 P/Share
|
|
Sep 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Sep 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.31%
|
$400,000
$4.71 P/Share
|
|
Sep 10
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
120,000
+10.05%
|
-
|
|
Aug 26
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$400,000
$4.84 P/Share
|
|
Aug 26
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Aug 18
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Open market or private sale
|
Direct |
36,599
-5.19%
|
$182,995
$5.52 P/Share
|
|
Aug 15
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,789
-0.53%
|
$18,945
$5.64 P/Share
|
|
Aug 15
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
40,390
-4.06%
|
$201,950
$5.64 P/Share
|
|
Aug 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,908
-1.45%
|
$59,540
$5.64 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
117,875
-100.0%
|
$589,375
$5.28 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
117,875
+50.0%
|
-
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
10,000
-1.0%
|
-
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
500,300
-33.24%
|
$2,501,500
$5.28 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
423,666
+21.97%
|
-
|
|
Jul 01
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,924
+2.11%
|
-
|
|
Jul 01
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,949
+0.16%
|
-
|
|
Jun 18
2025
|
Elaine D Sun Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,008
+18.8%
|
-
|
|
Jun 18
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,016
+1.75%
|
-
|
|
Jun 18
2025
|
Namandje Bumpus Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,008
+18.8%
|
-
|
|
Jun 18
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,016
+14.21%
|
-
|
|
Jun 18
2025
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,016
+22.99%
|
-
|
|
Jun 18
2025
|
Franziska Michor Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,016
+14.77%
|
-
|
|
Jun 18
2025
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,016
+0.31%
|
-
|
|
Jun 16
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,057
-0.85%
|
$28,228
$4.92 P/Share
|
|
May 15
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
36,197
-3.24%
|
$144,788
$4.25 P/Share
|
|
May 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,908
-1.41%
|
$47,632
$4.25 P/Share
|
|
May 15
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,796
-0.53%
|
$15,184
$4.25 P/Share
|
|
Apr 01
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,745
+2.42%
|
-
|
|
Apr 01
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,268
+2.77%
|
-
|
|
Apr 01
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,571
-3.06%
|
$132,855
$5.09 P/Share
|
|
Mar 27
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
138,574
-11.03%
|
$831,444
$6.04 P/Share
|
|
Mar 17
2025
|
Elaine D Sun Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,549
+50.0%
|
-
|
|
Mar 17
2025
|
Namandje Bumpus Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,549
+50.0%
|
-
|
|
Mar 17
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,057
-0.81%
|
$42,342
$6.84 P/Share
|
|
Mar 06
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-1.57%
|
$120,000
$6.37 P/Share
|
|
Mar 06
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+1.54%
|
-
|